Joachim Jankowski

Prof. Dr. Joachim Jankowski is Director of the Institute for Molecular Cardiovascular Research (IMCAR), a research institute localized inside the University Hospital of Aachen. The institute is dedicated to pursuing scientific excellence in the field of cardiovascular biology with special focus on chronic renal failure, vascular remodeling and cardiovascular disease. The IMCAR institute has built his expertise on transgenic mouse models of disease to study cardiovascular disease and vascular remodeling in an in vivo context, as well as on molecular and cellular biology to unravel associated pathological pathways. In addition, IMCAR has extensive expertise in mass spectrometry and chromatography aiming at the identification of novel prognostic factors for cardiovascular risk assessment and the identification and characterization of novel pharmaceutical targets. Prof. Dr. Joachim Jankowski has ample experience in research management. He is Co-Chair of the “European Uremic Toxin” (EUTox) working group, which is a subgroup of the "European Society of Artificial Organs" (ESAO), an endorsed working group of the "European Renal Association-European Dialysis Transplantation Association" (ERA-EDTA). He is board member of the ESAO too. He is coordinating e.g. the “New Tools for the Prevention of Cardiovascular Diseases and Disorders in Chronic Kidney Disease” (NTCVD) biobank embedded in the National Genome Research Network in Germany and the EU-ITN “Combatting the CardioRenal Syndrome: towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease” (CaReSyAn). In addition, he is professor at the School for Cardiovascular Diseases at University of Maastricht, The Netherlands. Also, he has an outstanding track record of participation/coordination in over 7 European research projects (EU Health), demonstrating long-standing research expertise in kidney diseases as well as CVD of patients with CKD.

Supervisor of project 5 – Characterisation of the recently identified "Calcification blocking factor" (CBF) and isolation of unknown mediators inhibiting calcification processes

Back to overview